Clinical Outcome of Gastric Cancer Patients with Bone Marrow Metastases
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose The prognosis of gastric cancer patients with bone marrow metastases is extremely poor. The current study was conducted to evaluate the clinical outcomes of advanced gastric cancer patients with bone marrow metastases. Materials and Methods We retrospectively reviewed the medical records of 26 advanced gastric cancer patients with bone marrow metastases who were treated at Soonchunhyang University Hospital between September 1986 and February 2009. Results The median age was 46 years (range, 24 to 61 years). All patients had poorly differentiated adenocarcinoma,including 17 signet ring cell carcinomas. The majority of the patients had thrombocytopenia,anemia, and elevated lactate dehydrogenase levels. Sixteen patients (61.5%) received palliative chemotherapy (median, 4 cycles; range, 1 to 13 cycles). The median overall survival after detection of bone marrow metastases for the cohort of patients was 37 days (95% confidence interval,12.5 to 61.5 days). The median overall survival after detection of bone marrow involvement was 11 days in the best supportive care group (range, 2 to 34 days) and 121 days (range, 3 to 383days) in the palliative chemotherapy group (p＜0.001). The causes of death were tumor progression (11 patients, 45%), brain hemorrhage (6 patients, 25%), infection (5 patients, 21%), and disseminated intravascular coagulation (1 patient, 4%). There were no chemotherapy-related deaths. Conclusion Palliative chemotherapy could be considered in advanced gastric cancer patients with bone marrow metastases as a treatment option.
Abstract
Purpose The prognosis of gastric cancer patients with bone marrow metastases is extremely poor. The current study was conducted to evaluate the clinical outcomes of advanced gastric cancer patients with bone marrow metastases. Materials and Methods We retrospectively reviewed the medical records of 26 advanced gastric cancer patients with bone marrow metastases who were treated at Soonchunhyang University Hospital between September 1986 and February 2009. Results The median age was 46 years (range, 24 to 61 years). All patients had poorly differentiated adenocarcinoma,including 17 signet ring cell carcinomas. The majority of the patients had thrombocytopenia,anemia, and elevated lactate dehydrogenase levels. Sixteen patients (61.5%) received palliative chemotherapy (median, 4 cycles; range, 1 to 13 cycles). The median overall survival after detection of bone marrow metastases for the cohort of patients was 37 days (95% confidence interval,12.5 to 61.5 days). The median overall survival after detection of bone marrow involvement was 11 days in the best supportive care group (range, 2 to 34 days) and 121 days (range, 3 to 383days) in the palliative chemotherapy group (p＜0.001). The causes of death were tumor progression (11 patients, 45%), brain hemorrhage (6 patients, 25%), infection (5 patients, 21%), and disseminated intravascular coagulation (1 patient, 4%). There were no chemotherapy-related deaths. Conclusion Palliative chemotherapy could be considered in advanced gastric cancer patients with bone marrow metastases as a treatment option.
참고문헌 (11)
- Hai-Rim Shin, "2002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 Hospitals", Cancer Research and Treatment, 36(2), pp.103~114 (2004), 대한암학회
- Crivellari D, "Gastric cancer with bone marrow invasion at presentation: case-report and review of the literature", Tumori, 81, pp.74~76 (1995)
- Noda N, "A case of bone marrow recurrence from gastric carcinoma after a nine-year disease-free interval", Jpn J Clin Oncol, 26, pp.472~475 (1996)
- Hayes DF, "Prognostic and predictive factors revisited", Breast, 14, pp.493~499 (2005)
- Kobayashi M, "Metastatic bone cancer as a recurrence of early gastric cancer: characteristics and possible mechanisms", World J Gastroenterol, 11, pp.5587~5591 (2005)
- Wiedswang G, "Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer", J Clin Oncol, 21, pp.3469~3478 (2003)
- Kusumoto H, "Characteristic features of disseminated carcinomatosis of the bone marrow due to gastric cancer: the pathogenesis of bone destruction", Oncol Rep, 16, pp.735~740 (2006)
- Tokar M, "Disseminated intravascular coagulation at presentation of advanced gastric cancer", Isr Med Assoc J, 8, pp.853~855 (2006)
- Pyrhönen S, "Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer", Br J Cancer, 71, pp.587~591 (1995)
- Glimelius B, "Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer", Ann Oncol, 8, pp.163~168 (1997)
- Kim HS, "Clinical outcome of gastric cancer patients with bone marrow metastases", ONCOLOGY, 73(3-4), pp.192~197 (2007), KARGER